A molecular biological rationale for the linear nonthreshold dose-response pattern for carcinogenesis is presented based on the mutagenic activation of oncogens as the basis of initiation. The approach assumes that the linear nonthreshold dose pattern at very low doses applies only to tissues that are promoted by intrinsic and extrinsic agents other than the one being modeled, and that risk is charactertized on a relative rather than absolute basis in terms of aggregate tumor response. 
Since this symposium is in honor of Norton Nelson I want to say a few words about him. I have known Norton Nelson for literally my entire professional life, going back 40 years when I was a cardiovascular fellow in the Department of Medicine with his war-time research buddy, the great Ludwig Eichna. Nelson recruited me in 1959 to the Institute, and I worked there over 20 years under his leadership. To put it in a word, he was a director of genius. The combination of a really powerful mind with an upbeat, forceful personality gave the Institute an intellectual glow that was a joy. It was greatly reassuring during all those years to know that the Institute was in the hands of someone who was, by far, the best in his field. His intellectual keenness, fund of knowledge, and grasp of an extraordinarily wide range of science was always a source of astonishment to me, and he was a model to emulate. As an administrator he was equally phenomenal with his ability to make decisions about complex matters almost instantly. I (2) . We proposed the idea a few years ago (3) that the linear nonthreshold extrapolation might apply to only the initiation process rather than to complete carcinogenesis.
The enthusiasm that greeted the notion was subliminal. However, the concept has revived with considerable force due to developments in molecular oncology. Of the various modes of activation of protooncogenes, namely, by insertion, amplification, translocation, and mutation, the mutational mode is the one that is highly consistent with a linear nonthreshold dose-response model. Moreover, the exciting finding was that the activation of ras oncogene by mutation generally of codon 61 or 12 is found in the early stage of the initiation promotion model in the mouse skin (4) . In other words, the activated ras oncogene is found in papillomas brought out in skin by PMA initiated with a polycyclic aromatic hydrocarbon, and the activation of the ras oncogene persists from papilloma to carcinoma.
This sequence of benign tumors that eventully become malignant is characteristic of an initiation-promotion system, and it is seen in human colon cancer. Here, polyps develop that eventually progress to carcinomas. It has been observed that in lesions where the original polyp and the carcinoma are seen together, the activated ras gene is present in both, which is the same circumstance as seen in the mouse initiation-promotion skin model (5). All of this suggests that a single hit process, namely, activation of the ras protooncogene by mutation, could be the initiating lesion in the carcinogenic process.
This puts a rather novel twist to a view of the doseresponse. It implies that at high doses there will be complete carcinogenesis. But, as the dose is diminished, the effect of the carcinogen is largely that of initiation because the promoting action fades away; whether tumors become manifest then depends on the amount of promotion present in the tissue from other sources. The implications are that there are two kinds of dose-response patterns: one in promoted tissues, where low doses will produce the sequence of benign to A simplified generalization would be to regard all tissues that show a background tumor occurrence as being promoted on the supposition that they must be promoted in order to develop tumors. The direct-acting agents with a high degree of reactivity would be localized to the organs of initial contact, while the others would be assumed to affect all tissues. It could be assumed that the aggregate tumor response induced in the animal would be translated to humans. Thus, the dose of 1,3-butadiene that causes a doubling of all tumors in the mouse would be assumed to double all tumors in humans. Agents that react only at initial sites of contact, such as formaldehyde, would be expected to have effects on background tumors only in that organ system in both animals and humans. For example, a formaldehyde exposure that doubles the background occurrence of spontaneous tumors in the rat nose would be expected to do the same in the human nose; in addition it would be expected to increase the background tumor yield in humans lower in the respiratory tract: the nasopharynx, larynx, and tracheobronchial tree in relation to the amount of dose that reaches these parts. Extrapolation to doses below the doubling dose would be done on a linear nonthreshold basis because of the experimental evidence developed. What is proposed here is a relative risk approach, compared to the absolute risk method currently being used. The proposed approach also tends to break away from the painting-by-thenumbers mentality that is characteristic of current carcinogen-assessment thinking. It 
